pond1
09 May 2018
Re: USA lost account means 20% drop Hi Biswell,My point exactly. It took Deltex many years (understandably) to gain contracts and to loose one without giving any reason is worrying.Hi Seadoc,My view re being in profit by end of first quarter of 2019, is 'I have no idea'. and as you say with no forward looking statements, points that the company have no idea either.
Fokisi
09 May 2018
Re: USA lost account means 20% drop "More cash is going to be needed yet again"I am wondering just how much more cash, and when...
biswell2
09 May 2018
USA lost account means 20% drop Who won the account that DEMG lost in the USA ?and Why did DEMG lose it ?After all DEMG only won the contract recently so what was the problem ?The results are not clear on what went wrong , and with UK sales falling again for 4 years in a row, one can only assume that one more USA lost account will mean the end for DEMG IMOMore cash is going to be needed yet again
seadoc
09 May 2018
Re: The results show Deltex's problem. Morning Pond,I do not think the share price will be soaring today but I continue to hold. Invoice discounting has largely disappeared, we now have pre-payment bartering. Is that a reflection of the shift to USA? You ask:"does anyone think that by year end, or even by the first quarter of 2019, the company will finally be in profit." My view is yes but there is the dog that did not bark - Last year the first half was good and second disappointing. We have had 4 out of 6 months of year to 2018. There is no mention in forward looking statements. That is not a good sign. It might become clearer in the formal annual report.Regards,Seadoc
pond1
09 May 2018
The results show Deltex's problem. Although throughout the year we have seen increased contracts, mainly in the USA the company is still not in profit, although we were told that profit was near a couple of years ago.Operating loss is still evident but reduced by £0.4m to £2.0m (2016: £2.4m), so loss only reduced by 20%.Group revenues £0.4m lower at £5.9m (2016: £6.3m) one has to wonder why, if they have more units and probes being used.Even with gross margins improved to 75% (2016: 68%) the company is still loosing money.With statements such as 'Revenues from US managed care contracts down 20% at £0.4m (2016: £0.5m) due to one lost account' '2017 was partially offset by a disappointing second half sales performance'. You have to wonder why they are loosing accounts if the system is as good and cost effective as the company states (I do believe it is as good as we have been told, so there's the mystery.I have never seen a product that has so many positive trials and feedback fail so miserably to almost by results contradict the figures from those trials.As many of us have stated, It can only be down to the companies business model. Can anyone can give a better explanation. Also does anyone think that by year end, or even by the first quarter of 2019, the company will finally be in profit.With the separate release re the TrueVueTM System, (which I read first finishing with a positive feeling that was reversed on reading the results) I still feel the SP will either open down, or if upward will as ever drift ever downward again.
seadoc
08 May 2018
Re: Will this follow the usual trend. Pond,We will find out at 0700 tomorrow.Regards,Seadoc
pond1
17 Apr 2018
Will this follow the usual trend. More upward movement today of 7.5% with an increase (although not great) in trades, mainly buys.If this follows usual trends, an RNS re very small contract will follow, and a few days later by a drop back to pre rise price of 1.32p.Will this sleeping dog keep getting up, walking a few steps then laying down again.They say, let sleeping dogs lie, but I would love to give this dog an almighty kick.
pond1
13 Apr 2018
Re: Control - Henderson These RNS re shareholding are about as clear as mud. I often feel that they are designed more to confuse than to clarify.
seadoc
13 Apr 2018
Re: Control - Henderson Henderson seen to have acquired voting rights on 25m shares:EMG/news/item/2705307/holdings-company?context=LSE
EMGNot" target="blank" rel="nofollow">[link] sure if art 10 refers to only options or if it includes shares bought by subsidiaries (which I guess is the case). Anyone know? Even the combined help of Mr Google and Mr Wiki failed me.Regards,Seadoc
seadoc
02 Mar 2018
Re: Control Fokisi,They were only looking for £500k, they probably found most of that down the back of the fund manager's sofa. But as you point out it is interesting that there is no RNS showing a significant holding but if fund holders took up a proportion in relation to their shareholding there would be no levels crossed and no need for RNS. In the last annual accounts there is no table of major holders. The last RNS for major holder were mid 2017 Herald and Hambro. Regards,Seadoc
Fokisi
02 Mar 2018
Control Who were group of investors providing funds for recent placement of shares, anyone know?
pond1
01 Mar 2018
Re: Research Reports - Thoughts Please I have also often thought why the company has not been taken over if the product is so good.Even in the UK where the NHS appears to always purchase items at a top price yet still tends to overlook the CardioQ I find it hard to work out why the private sector has not been more of a customer.The system has been proven many times to save lives, reduce re-admittance, shorten recovery times and therefore also save money, so it is difficult to see any reasons why it does not sell.I agree that it may be slightly difficult to use but so are many other innovations that have been taken up and are now in regular use. I still think that the product is not the problem, but something must be.
Hangover2
01 Mar 2018
Thanks A most useful and precise answer and dipped my toe back into Deltex!
wigwammer
01 Mar 2018
Re: Research Reports - Thoughts Please Hi hangover, you are correct IMO - if the proposition is a good as some have long suggested then the technology would have been bought out. Researching over the recent statements I think the reality is - the product is good but it requires skill to use it and is only practical in asleep patients because of the gag reaction. This means the technology is difficult to introduce across a hospital, from nurse to surgeon and between asleep/awake patients. They are trying to ameliorate this hurdle by combining ODM with easier to use technologies like ppwa - particularly for monitoring - while at the same time pushing for greater adoption of ODM by surgeons as an intervention tool. Hopefully over time, the techniques are better understood and can spread down the chain. Ewan has just purchased a substantial number of shares, the first time he has done so as far back as I can remember - which suggests that those really in the know believe things may be on the up. Fingers crossed
Hangover2
01 Mar 2018
Research Reports - Thoughts Please I held this share years ago and got out at a loss.As stated research such as this should be compelling and over the years it has come from many institutions in many countries.The management may be awful at getting the product into hospitals - have the wrong strategy etc. but why if the product is good does Deltex not become a takeover target? Is that not capitalisms supposed route of removing poor management teams - I assume most shareholders offered a reasonable price may sell?I am very close to buying again some 5 or so years after I sold out on the basis that I see lots of new starts with ridiculous valuations and this surely has value buried within it and my past experience IQE being one is sometimes you can give up too early....if I owned I'd definitely hold and I'm tempted to join those that do!
